Krka, d. d.

WSE:KRK Stock Report

Market Cap: zł18.3b

Krka d. d Valuation

Is KRK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KRK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KRK (PLN602) is trading below our estimate of fair value (PLN740.4)

Significantly Below Fair Value: KRK is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KRK?

Key metric: As KRK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for KRK. This is calculated by dividing KRK's market cap by their current earnings.
What is KRK's PE Ratio?
PE Ratio11.8x
Earnings€359.83m
Market Cap€4.24b

Price to Earnings Ratio vs Peers

How does KRK's PE Ratio compare to its peers?

The above table shows the PE ratio for KRK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average59.1x
CLN Celon Pharma
78.7x14.4%zł1.5b
KLBF Kalbe Farma
22.5x9.6%Rp69.2t
BGD Biogened
11.1xn/azł54.0m
600518 Kangmei Pharmaceutical
124.2xn/aCN¥31.7b
KRK Krka d. d
11.8x4.0%zł4.2b

Price-To-Earnings vs Peers: KRK is good value based on its Price-To-Earnings Ratio (11.8x) compared to the peer average (59.1x).

Price to Earnings Ratio vs Industry

How does KRK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
KRK 11.8xIndustry Avg. 20.1xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: KRK is good value based on its Price-To-Earnings Ratio (11.8x) compared to the European Pharmaceuticals industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is KRK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KRK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.8x
Fair PE Ratio71.9x

Price-To-Earnings vs Fair Ratio: KRK is good value based on its Price-To-Earnings Ratio (11.8x) compared to the estimated Fair Price-To-Earnings Ratio (71.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KRK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł602.00
zł575.04
-4.5%
12.5%zł669.65zł496.84n/a6
Nov ’25zł586.00
zł568.97
-2.9%
12.5%zł662.58zł491.59n/a6
Oct ’25zł578.00
zł568.97
-1.6%
12.5%zł662.58zł491.59n/a6
Sep ’25zł584.00
zł567.44
-2.8%
11.4%zł646.37zł495.55n/a6
Aug ’25zł604.00
zł564.09
-6.6%
11.8%zł645.00zł481.60n/a6
Jul ’25zł608.00
zł559.65
-8.0%
11.8%zł639.76zł477.69n/a6
Jun ’25zł548.00
zł559.65
+2.1%
11.8%zł639.76zł477.69n/a6
May ’25zł540.00
zł580.12
+7.4%
11.8%zł651.14zł494.87n/a5
Apr ’25zł558.00
zł580.12
+4.0%
11.8%zł651.14zł494.87n/a5
Mar ’25zł520.00
zł580.12
+11.6%
11.8%zł651.14zł494.87n/a5
Feb ’25zł500.00
zł541.75
+8.4%
13.5%zł652.19zł458.71n/a5
Jan ’25zł483.00
zł518.75
+7.4%
9.4%zł600.72zł457.59n/a5
Dec ’24zł466.00
zł523.27
+12.3%
9.3%zł604.94zł460.81n/a5
Nov ’24zł472.00
zł554.62
+17.5%
9.3%zł641.19zł488.42zł586.005
Oct ’24zł500.00
zł522.46
+4.5%
6.3%zł557.71zł470.71zł578.005
Sep ’24zł472.00
zł522.46
+10.7%
6.3%zł557.71zł470.71zł584.005
Aug ’24zł504.00
zł522.46
+3.7%
6.3%zł557.71zł470.71zł604.005
Jul ’24zł518.00
zł523.40
+1.0%
7.5%zł567.43zł478.91zł608.005
Jun ’24zł504.00
zł523.40
+3.8%
7.5%zł567.43zł478.91zł548.005
May ’24zł532.00
zł532.83
+0.2%
10.5%zł589.94zł443.64zł540.005
Apr ’24zł510.00
zł532.83
+4.5%
10.5%zł589.94zł443.64zł558.005
Mar ’24zł496.00
zł532.83
+7.4%
10.5%zł589.94zł443.64zł520.005
Feb ’24zł502.00
zł492.54
-1.9%
6.4%zł541.51zł442.63zł500.005
Jan ’24zł435.00
zł490.15
+12.7%
6.4%zł539.62zł440.31zł483.005
Dec ’23zł445.00
zł495.36
+11.3%
5.3%zł541.21zł460.41zł466.005
Nov ’23zł434.00
zł498.62
+14.9%
6.4%zł551.39zł469.06zł472.004

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies